SUMMARY Raised serum alkaline phosphatase (AP) levels were found in 13 of 76 patients (17 %) with ankylosing spondylitis (AS), and 1 1 of these 13 underwent further investigation to determine the origin of the increased enzyme activity. Three had levels within the normal reference range on re-estimation, and, of the remaining 8, AP isoenzyme studies indicated an increased liver fraction in 6. Serum gamma-glutamyl transpeptidase (GGT) was raised in only 3 patients. Increased AP activity did not appear to be directly related to disease activity or to drug therapy. These findings confirm the occurrence of increased serum AP activity in AS but challenge a previously reported suggestion that bone is the source of the increased enzyme.
The serum level of alkaline phosphatase (AP) may rise in a variety of inflammatory rheumatic diseases.' 2 The source of the increased enzyme activity is usually the liver,`-4 but it has been suggested that it arises from bone in ankylosing spondylitis (AS).' We have investigated the prevalence of raised AP in AS and attempted to determine the origin of the increased enzyme activity by isoenzyme studies and by reference to other liver enzymes, specifically alanine transaminase (ALT) and gamma-glutamyl transpeptidase (GGT).
Patients and methods
Sixty-seven men and 9 women, aged 18-71 years, with AS as defined by the New York criteria, were assessed clinically, haematologically, and biochemically. Five had associated psoriasis, 2 Reiter's disease, and 4 chronic inflammatory bowel disease. The mean duration of spondylitic symptoms was 14-9 years.
The initial laboratory investigations included haemoglobin, full blood count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and a serum biochemical screen for calcium, phosphate, AP, total protein, albumin, bilirubin, and ALT. Repeats of these tests with additional AP isoenzyme studies and estimation of GGT were performed on patients found to have AP levels above 13 KingAccepted for publication 6 
Results
Thirteen patients (17%) had AP levels above the upper limit of the reference range, and 11 (see Table  1 ) returned for further investigation. Eight other patients had borderline values of 13 KAU/dl and were not retested. Of the 11, 3 had a normal AP on the second occasion. In the other 8 the isoenzyme studies indicated an increased liver fraction in 6, an 563 Several nonsteroidal anti-inflammatory drugs are known to be potentially hepatotoxic, with reports of liver damage ranging from transitory mild disturbances of liver function tests to fatal hepatitis and intrahepatic cholestasis," 12 but drug therapy did not appear to be implicated in the disturbance of AP activity in our patients. Four of these with elevated levels were not receiving anti-inflammatory medication, and the 3 whose values were normal on rescreening were on no medication at the time when their AP levels were raised.
The significance of increased AP activity in AS remains obscure, but it may simply be a nonspecific reaction to the inflammatory process. It would appear that small increases do not warrant further investigation, but, when high levels are found in apparently uncomplicated spondylitis, primary hepatic disease and drug toxicity should be excluded.
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